Redefining Iron Deficiency in Patients With Chronic Heart Failure
Open Access
- 9 July 2024
- journal article
- review article
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (2) , 151-161
Abstract
A serum ferritin level <15 to 20 μg/L historically identified patients who had absent bone marrow iron stores, but serum ferritin levels are distorted by the systemic inflammatory states seen in patients with chronic kidney disease or heart failure. As a result, nearly 25 years ago, the diagnostic ferritin threshold was increased 5- to 20-fold in patients with chronic kidney disease (ie, iron deficiency was identified if the serum ferritin level was <100 μg/L, regardless of transferrin saturation [TSAT], or 100 to 299 μg/L if TSAT was <20%). This guidance was motivated not by the findings of studies of total body or tissue iron depletion, but by a desire to encourage the use of iron supplements to potentiate the response to erythropoiesis-stimulating agents in patients with renal anemia. However, in patients with heart failure, this definition does not reliably identify patients with an absolute or functional iron-deficiency state, and it includes individuals with TSATs (≥20%) and serum ferritin levels in the normal range (20–100 mg/L) who are not iron deficient, have an excellent prognosis, and do not respond favorably to iron therapy. Furthermore, serum ferritin levels may be distorted by the use of both neprilysin and sodium-glucose cotransporter 2 inhibitors, both of which may act to mobilize endogenous iron stores. The most evidence-based and trial-tested definition of iron deficiency is the presence of hypoferremia, as reflected by as a TSAT <20%. These hypoferremic patients are generally iron deficient on bone marrow examination, and after intravenous iron therapy, they exhibit an improvement in exercise tolerance and functional capacity (when meaningfully impaired) and show the most marked reduction (ie, 20%–30%) in the risk of cardiovascular death or total heart failure hospitalizations. Therefore, we propose that the current ferritin-driven definition of iron deficiency in heart failure should be abandoned and that a definition based on hypoferremia (TSAT <20%) should be adopted.Keywords
This publication has 99 references indexed in Scilit:
- How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failureEuropean Journal of Heart Failure, 2022
- Effect of dapagliflozin on anaemia in DAPA‐HFEuropean Journal of Heart Failure, 2021
- High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortalityEuropean Journal of Heart Failure, 2020
- Anaemia, Iron Status, and Gender Predict the Outcome in Patients with Chronic Heart FailureESC Heart Failure, 2020
- Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart FailureJAMA Cardiology, 2019
- Prevalence of Underlying Gastrointestinal Malignancies in Iron-Deficient Heart FailureESC Heart Failure, 2018
- Iron Deficiency Impairs Contractility of Human Cardiomyocytes Through Decreased Mitochondrial FunctionEuropean Journal of Heart Failure, 2018
- Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron DeficiencyJAMA, 2017
- Prevalence and Outcomes of Anemia and Hematinic Deficiencies in Patients With Chronic Heart FailureJAMA Cardiology, 2016
- Diagnosis of Iron Deficiency Anemia in the Elderly by Transferrin Receptor–Ferritin IndexArchives of internal medicine (1960), 2002